NCT01445535 2021-11-03Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell LymphomasNational Institutes of Health Clinical Center (CC)Phase 1 Completed15 enrolled 18 charts
NCT00105313 2007-06-14Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/LeukemiaMedImmune LLCPhase 1 Terminated80 enrolled